Performance of host-response biomarkers to risk-stratify children with pneumonia in Bhutan

Sophie Jullien1, Melissa Richard-Greenblatt2, Michelle Ngai3

  • 1Institut de Salut Global de Barcelona (ISGlobal), Universitat de Barcelona (UB), Barcelona, Spain; Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain; Jigme Dorji Wangchuck National Referral Hospital, Thimphu, Bhutan.

The Journal of Infection
|October 15, 2022
PubMed

Insights

A new biomarker, soluble triggering receptor expressed on myeloid cells 1 (sTREM-1), can identify children with pneumonia at high risk of severe disease. This tool aids early referral and resource allocation for better child survival outcomes.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Biomarkers

Background:

  • Pneumonia is a leading cause of death in children under five globally.
  • A simple triage tool is needed to identify children at risk of severe or fatal pneumonia.
  • Early identification can improve outcomes and resource allocation.

Purpose of the Study:

  • To compare inflammatory and endothelial activation markers with clinical signs for risk-stratifying children hospitalized with pneumonia.
  • To identify a predictive tool for clinical outcomes in pediatric pneumonia.

Main Methods:

  • 118 children hospitalized with pneumonia were studied.
  • Performance of biomarkers (including sTREM-1) and clinical parameters was assessed.
  • Poor prognosis was defined by mortality, PICU admission, chest drainage, or prolonged oxygen therapy.

Main Results:

  • 31 out of 118 children had a poor prognosis.
  • Soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) demonstrated superior performance compared to clinical parameters.
  • sTREM-1 levels upon admission showed good predictive accuracy for poor prognosis.

Conclusions:

  • Immune and endothelial activation markers, particularly sTREM-1, can serve as effective risk-stratification tools in pediatric pneumonia.
  • These biomarkers may aid clinical decision-making at initial patient encounters.
  • Further external validation of these findings is recommended.